Our study demonstrates that AKT activation and increased levels of ROS in CLL cells are critical downstream mediators of SHIP1 inhibition in CLL resulting in a lytic form of cell death. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.